The objective of this Phase 2 study is to evaluate the efficacy of methylene blue photodynamic therapy (MB-PDT) performed at the time of percutaneous breast abscess drainage for disinfection of breast abscesses. The study includes two arms: (1) standard of care breast abscess drainage and (2) MB-PDT plus standard of care breast abscess drainage. The primary endpoint is time to resolution of clinical symptoms. Secondary endpoints include imaging evidence of abscess resolution, abscess recurrence, need for repeated intervention, and cure rate across treatment groups. Responses will be compared between the two study arms for the per protocol population to determine the efficacy of MB-PDT relative to standard of care. We hypothesize that the addition of MB-PDT to standard of care will significantly reduce the time to symptom resolution, compared to standard of care alone.

开始日期2026-04-01

申办/合作机构

University of Rochester

NCT06052956

/ Not yet recruiting临床2期IIT

A Phase 2 Study to Assess Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses

The objective of this Phase 2 study is to evaluate the efficacy of methylene blue photodynamic therapy (MB-PDT) performed at the time of percutaneous abscess drainage for disinfection of deep tissue abscesses. The study includes three arms: (1) MB-PDT at a fixed drug/light dose plus standard of care abscess drainage , (2) MB-PDT at a patient-specific dose determined by pre-treatment optical measurements plus standard of care abscess drainage , and (3) standard of care abscess drainage. The primary endpoint is reduction in time to removal of the drainage catheter.

开始日期2025-12-15

申办/合作机构

University of Rochester

ChiCTR2500109353

临床1期IIT

The Effectiveness and Safety of Methylene Blue Enteric-Coated Sustained-Release Tablets on Colorectal Screening in Patients with metabolic syndrome: A Prospective, Randomized, Placebo-Controlled, Single-Center Clinical Study

开始日期2025-10-01

申办/合作机构-

100 项与亚甲蓝相关的临床结果

登录后查看更多信息

100 项与亚甲蓝相关的转化医学

登录后查看更多信息

100 项与亚甲蓝相关的专利（医药）

登录后查看更多信息

59,974

项与亚甲蓝相关的文献（医药）

2025-12-31·ANNALS OF MEDICINE

The mystery of methylene blue and its role in managing post-cardiac surgery vasoplegic shock

Article

作者: Heim, Christian ; Elbayomi, Mohamed ; Tandler, Rene ; Weyand, Michael ; Pathare, Presheet ; Kondruweit, Markus ; Dewald, Oliver

BACKGROUND:

Vasoplegic syndrome is associated with high mortality. Methylene blue (MB) is a guanylate cyclase inhibitor that ameliorates this re-distributive type of shock. This study aims to investigate the outcome in patients who received MB early postoperatively.

METHODS:

2753 patients who underwent cardiac surgery utilizing cardiopulmonary bypass at our institution in a time interval of two years were identified. The incidence of vasoplegic syndrome was 7.2% (n = 200). Pharmacy records identified 84 patients (group 1, MB group) who received methylene blue and 116 patients (group 2, Control group) who didn't receive the drug. This single-center retrospective cohort study's primary outcome was in-hospital mortality. Secondary outcomes were postoperative hemodialysis, serum lactate levels at 24 h postoperatively, and intensive care unit stay length in days.

RESULTS:

MB patients have a shorter ICU stay as compared to the control group (9 ± 8 days vs. 16 ± 6.9; p-value <.001). In the control group, postoperative hemodialysis was higher (20% in the MB group and 40% in the control group; p-value <.05). At 24 h post-op, the methylene blue group had reduced serum lactate levels (1.8 ± 1.2 vs. 4 ± 1.8 in the control group; p-value <.001). The methylene blue group had a decreased 24-hour norepinephrine dose (1.5 ± 1.2 vs. 2.8 ± 2 in the control group; p-value <.05). In-hospital mortality was not significantly different between the two groups (38% in the MB group vs. 43% in the control group).

CONCLUSION:

Early postoperative administration of methylene blue in patients with vasoplegic syndrome shortens intensive care unit stay and contributes to less end-organ damage.

2025-12-31·SCIENCE AND TECHNOLOGY OF ADVANCED MATERIALS

Enhancement of photocatalytic efficiency of copper oxide/zinc oxide-montmorillonite photocatalyst under visible light irradiation

Article

作者: Khaorapapong, Nithima ; Suppaso, Chomponoot ; Yamauchi, Yusuke ; Baoulan, Areebhorn ; Pongkan, Nipaporn ; Rattanawongsa, Wachiraya ; Asakura, Yusuke ; Intachai, Sonchai

The formation of copper oxide and zinc oxide mixture in montmorillonite was conducted by the reaction of an aqueous dispersion of Cu²⁺/Zn²⁺ exchanged montmorillonite and an aqueous solution of sodium hydroxide under hydrothermal treatment. The resulting product was characterized by X-ray diffraction, scanning and transmittance electron microscopies, as well as UV-visible and photoluminescence spectroscopies. The diffuse reflectance absorption spectra showed the absorption onsets due to copper oxide (885 nm) and zinc oxide (310 and 580 nm) in the product. The adsorption of methylene blue was fitted well by the Langmuir model with the maximum adsorption capacity of 454 mg⋅g^-1. The thermodynamic studies revealed that the process is exothermic and spontaneous. The photocatalytic activity of the hybrid was assessed by the degradation of methylene blue in aqueous solution under visible light irradiation. The most active species in the photocatalytic process was hydroxyl radicals. The regenerated copper oxide/zinc oxide-montmorillonite was reused up to 5 cycles, the photodegradation efficiency dropped only 5% (from 94% to 89%), supporting the good stability of the photocatalyst. The result was in agreement with the advantages of the nanocomposite heterostructure and the unique nature of montmorillonite.

2025-12-01·Techniques in Coloproctology

The use of a methylene blue and glyceryl trinitrate-based cream for the treatment of chronic anal fissures: a phase II randomized pilot trial from a referral coloproctological unit

Article

作者: Laforgia, R ; Lobascio, P ; Pezzolla, A ; Tomasicchio, G ; Cassetta, N ; Altomare, D F ; Gallo, G

BACKGROUND:

Chronic anal fissures (CAFs) are the second most common anorectal disease. Non-surgical treatment includes several options with controversial efficacy. The aim of this study was to evaluate the efficacy and safety of a new ointment based on methylene blue in addition to glyceryl trinitrate.

METHODS:

A phase II randomized single-centre triple-blinded study was carried out in a tertiary proctology unit on patients with CAF. The enrollment started after local ethics committee approval (study n. 6461, protocol approval n. 0045085). Eligible consecutive patients were randomized to one of three different groups, each receiving a different ointment. The efficacy of the treatment was evaluated with the REALISE score.

RESULTS:

Nine patients were treated with cream A (median age 47 years, IQR 40-56, 22% female), nine with cream B (median age 52 years, IQR 49-57, 33% female), and nine with cream C (median age 58 years, IQR 46-62, 55% female). In group A, REALISE scores decreased significantly from a median of 22 (IQR 12-25) to 6 (IQR 4-8) (p < 0.05) after 40 days. In group B, REALISE scores improved significantly from a median of 20 (IQR 17-22) to 5 (IQR 4-9) (p < 0.05). In group C, REALISE scores decreased significantly from a median of 19 (IQR 19-20) to 4 (4-5) (p < 0.05). No statistically differences were recorded. The healing rate was 77% with creams A and C, while it was 44% with cream B.

CONCLUSION:

Methylene blue-based ointments could be a new and innovative treatment for the non-operative management and healing of CAFs.

项与亚甲蓝相关的新闻（医药）

2025-08-13

·米内网

【火热】南京正大天晴首家报产，$1.4亿明星药首仿战来了

精彩内容近日，南京正大天晴制药提交了艾拉戈克钠片3类仿制上市申请获得CDE承办。艾拉戈克钠片是艾伯维的潜力产品，原研药暂未进入中国市场，南京正大天晴制药是该产品首家申报仿制上市的国内药企。今年以来，南京正大天晴制药已累计报产了14个高端仿制药，公司将参与其中10个产品的国内首仿争夺。图1：南京正大天晴制药最新申报的产品来源：CDE官网据悉，艾拉戈克钠片是一种促性腺激素释放激素（GnRH）受体拮抗剂，广泛应用于中度至重度子宫内膜异位症引起的疼痛患者的治疗，原研产品于2018年获FDA批准上市，是近十年首个获批用于上述适应症的口服疗法。图2：艾拉戈克钠片的全球销售情况来源：米内网跨国上市公司数据库艾拉戈克钠片（又名艾拉戈利）近几年在全球的销售额持续攀升，2020年突破1亿美元，2021年涨至1.45亿美元。米内网数据显示，目前原研的艾拉戈克钠片暂未在国内申报，但已吸引到了7家国内药企布局。从申报时间来看，齐鲁制药（海南）最早在2021年12月提交3类仿制临床申请并于2022年3月获批，随后成都倍特药业、南京正大天晴制药、浙江华海药业、丽珠集团丽珠制药、东莞松山湖美健生物技术陆续获批临床，2025年6月金陵药业南京金陵制药也加入了战局，目前临床申请正在审评审批中。图3：南京正大天晴制药的艾拉戈克钠片的项目进度来源：米内网项目进度数据库 7家国内药企陷入激战，南京正大天晴制药先拔头筹，2025年8月9日公司首家提交艾拉戈克钠片的3类仿制上市申请，抢首仿有时间优势。表1：今年以来南京正大天晴制药申报上市的新产品来源：米内网中国申报进度（MED）数据库今年以来，南京正大天晴制药已累计报产了14个高端仿制药，其中八氟丙烷脂质微球注射液、蔗糖羟基氧化铁咀嚼片、亚甲蓝肠溶缓释片、佩玛贝特片、西达本胺片、依伏卡塞片、呋喹替尼胶囊7个产品目前仅有原研药获批（含国产原研），左卡尼汀咀嚼片、醋酸钠林格葡萄糖注射液(Ⅰ)、艾拉戈利钠片3个产品暂未有原研药或国产仿制药获批上市，南京正大天晴制药将参与上述10个产品的国内首仿争夺，公司的首仿药矩阵有望新添多个重磅产品。资料来源：米内网数据库、CDE官网注：数据统计截至8月12日，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

上市批准专利侵权

2025-08-12

·医药代表

《2025商保创新药目录》来了，121个品种通过“初审”！

通过“初审”的《2025 商保创新药目录》公布了，共有 121 个品种。今日，国家医保局发布《关于公示通过2025年国家基本医疗保险、生育保险和工伤保险药品目录及商保创新药目录调整初步形式审查的药品及相关信息的公告》（见今日另一则推送），其中，通过 2025 年《商保创新药目录》初步形式审查的申报药品有 121 个，具体如下：简要编号及名称 041-泽美洛韦玛佐瑞韦单抗注射液 044-复方氨基酸(19)丙谷二肽注射液 048-复方氨基酸注射液(17AA-Ⅱ) 057-亚甲蓝肠溶缓释片 058-聚卡波非钙颗粒 062-那西妥单抗注射液 068-岭南万应豆蔻膏 069-纳基奥仑赛注射液 075-醋酸格拉替雷注射液 077-氢溴酸他泽司他片 087-罗培干扰素α-2b注射液 091-注射用赤芝孢子多糖 097-钇[90Y]微球注射液 099-酒石酸伐尼克兰鼻喷雾剂 100-泽沃基奥仑赛注射液 115-多奈单抗注射液 116-左乙拉西坦缓释颗粒 121-锝[99mTc]替曲膦注射液 132-托夫生注射液 133-醋酸阿比特龙片(Ⅱ) 144-普特利单抗注射液 146-奥拉西坦片 149-阿基仑赛注射液 154-罗替高汀贴片 156-注射用头孢哌酮钠他唑巴坦钠(Ⅱ) 164-注射用替度格鲁肽 165-瑞基奥仑赛注射液 168-石杉碱甲注射液 176-注射用坦昔妥单抗 178-奥拉西坦葡萄糖注射液 179-奥拉西坦氯化钠注射液 190-盐酸伊立替康脂质体注射液(Ⅱ) 192-卡波姆产道凝胶 194-注射用西维来司他钠 205-盐酸替扎尼定口服溶液 210-艾度硫酸酯酶β注射液 212-四价流感病毒亚单位疫苗 217-枸橼酸倍维巴肽注射液 218-氯马昔巴特口服溶液 223-注射用维拉苷酶β 231-盐酸拉贝洛尔氯化钠注射液 242-盐酸伐地那非口崩片 243-阿得贝利单抗注射液 244-注射用戈沙妥珠单抗 251-赛立奇单抗注射液 252-布洛芬氯化钠注射液 258-磷酸二氢钠磷酸氢二钠颗粒 261-特立妥单抗注射液 262-塔奎妥单抗注射液 263-普拉替尼胶囊 274-去铁酮片 276-达妥昔单抗β注射液 277-波哌达可基注射液 289-依达拉奉舌下片 293-盐酸依特卡肽注射液 299-舒格利单抗注射液 304-甲苯磺酸他拉唑帕利胶囊 310-硫酸瑞美吉泮口崩片 318-埃纳妥单抗注射液 321-注射用奥加伊妥珠单抗 327-卡匹色替片 334-注射用维拉苷酶α 336-斯泰度塔单抗注射液 339-瑞利珠单抗注射液 342-斯鲁利单抗注射液 345-奥木替韦单抗注射液 355-盐酸沙丙蝶呤片 358-索卡佐利单抗注射液 361-贝莫苏拜单抗注射液 365-注射用泽尼达妥单抗 368-注射用贝林妥欧单抗 370-吸入用一氧化氮 374-苯丁酸钠颗粒 378-氯化镭[²²³Ra]注射液 381-艾美赛珠单抗注射液 382-人促甲状腺素注射液 389-阿替利珠单抗注射液 392-注射用石杉碱甲 394-伊基奥仑赛注射液 395-伐莫洛龙口服混悬液 396-利伐沙班口崩片 400-注射用罗替高汀微球 403-氨氯地平氯沙坦钾片(Ⅰ) 404-氨氯地平氯沙坦钾片(Ⅱ) 406-芦沃美替尼片 407-氟[18F]贝他苯注射液 411-甲苯磺酰胺注射液 413-奥德昔巴特胶囊 417-托伐普坦口崩片 423-加那索龙口服混悬剂 432-注射用芦比替定 440-比奇珠单抗注射液 442-恩考芬尼胶囊 448-注射用伏欣奇拜单抗 450-盐酸替那帕诺片 455-伊努西单抗注射液 456-依若奇单抗注射液 461-雌二醇地屈孕酮片 467-贝组替凡片 468-注射用亚胺西瑞 477-富马酸吉瑞替尼片 478-注射用人干扰素γ 480-注射用维恩妥尤单抗 484-莱博雷生片 485-仑卡奈单抗注射液 486-多替诺雷片 488-司美格鲁肽片 495-口服用苯丁酸甘油酯 496-莫格利珠单抗注射液 498-二氮嗪口服混悬液 500-氯法拉滨注射液 501-布罗索尤单抗注射液 504-埃万妥单抗注射液 509-聚乙二醇重组人生长激素注射液 516-依达拉奉右莰醇舌下片 518-注射用苏维西塔单抗 519-盐酸达利雷生片 522-当归补血汤颗粒 526-维生素K1滴剂 531-伊匹木单抗注射液 532-纳武利尤单抗注射液 ▌ 商保创新药目录今年 7 月 1 日，国家医保局发布 2025 年国家医保药品目录调整工作方案（征求意见稿），商保创新药目录第一次出现在工作方案中（见 MRCLUB 历史消息：刚刚，2025国家医保药品目录调整工作方案来了）。同日，国家医保局、国家卫生健康委发布关于印发《支持创新药高质量发展的若干措施》的通知（医保发〔2025〕16号）（见 MRCLUB 历史消息：创新药要起飞啦！国家发布目录准入、挂网、进院支持政策）。其中提到，适应多层次医疗保障体系发展需要，增设商业健康保险创新药品目录，重点纳入创新程度高、临床价值大、患者获益显著且超出基本医保保障范围的创新药，推荐商业健康保险和医疗互助等多层次医疗保障体系参考使用。通过协商合理确定商保创新药目录内药品结算价，探索更严格的价格保密机制。商保创新药目录内药品不计入基本医保自费率指标和集采中选可替代品种监测的范围。统筹做好商保创新药目录与医保目录的衔接。当日上午，国家医保局举行“支持创新药高质量发展的若干措施”新闻发布会（见 MRCLUB 历史消息：创新药有方向了！国家医保局新闻发布会文字实录），其中在回答记者提问中提到，随着医药技术创新发展和医疗服务水平提升，确有一小部分临床效果显著、创新程度高的药品因超出基本医保保障能力暂时无法纳入保障范围。为此，制定出台商业健康保险创新药品目录，提高药品的可及性，更好满足人民群众多层次用药保障需求。医保局相关负责人表示，从制定程序上看，商保创新药目录由国家医保局组织制定，将充分发挥医保目录调整专家优势、减轻医药企业多头申报的事务性负担，考虑与医保目录同时申报、同步调整，程序基本一致。企业可自主申报纳入医保目录或纳入商保创新药目录，也可同时申报两者。与医保目录调整的不同点在于，商保创新药目录将充分尊重商业健康保险公司的市场主体地位，在方案制定、专家评审、价格协商等各环节保险公司、行业专家等将充分参与的机制。商业健康保险专家对药品是否进入商保创新药目录以及价格协商具有重要决策权。 7 月 11 日，国家医保局发布正式版的 2025 年国家医保药品目录调整工作方案（见 MRCLUB 历史消息：正式版来了！2025国谈时间确定，更多问题官方解答→），以及相关的《谈判药品续约规则》、《非独家药品竞价规则》、《常见问答》。对于大家比较关心的商保目录，正式版《工作方案》进行了说明，参与价格协商的商保创新药品按模板提交材料，专家开展测算评估后提出协商价格的评估意见。组织企业进行现场价格协商，协商成功的药品纳入商保创新药目录，并签署协议。协商规则、具体协议条款将在征求相关方意见后另行确定。今日，国家医保局公布了通过初步形式审查的《商保创新药目录》，据官方解读（见今日另一则消息），形式审查只是企业申报后目录调整所有程序中的第一步。一个药品通过初步形式审查，只代表初审符合相应申报条件，还需要通过公示接受社会监督，即使药品最终确定通过形式审查，也仅代表该药品具备了参与目录调整后续工作流程的资格，不代表其已经纳入了基本医保目录或商保创新药目录。相关阅读： AZ前高管加盟，百时美施贵宝迎来新任CMO 阿斯利康中国，架构调整拜耳新一轮招聘启动，这次机会不要错过中央巡视组进驻，前省卫健委主任主动投案 18家药企上榜2025年《财富》世界500强诺和诺德新任总裁兼首席执行官确定国家药监局原副局长陈时飞被开除党籍医疗反腐，这两天多人被查中央巡视组入驻，一卫健委副主任任上被查搞钱色交易等，医科大学副校长被双开住友制药宣布，完成中国区业务剥离限期60天！17位跨国药企CEO收“降价信” 默沙东，将裁员6000人！骨科主任受贿287万，虚报耗材集采量被查涉回扣，一药企一械企被通报赛默飞携手AI公司，探索罕见病新药开发 162个品规！第十一批国采开始报量啦国药集团一公司致歉，相关人员已调整一外企更换大中华区总经理，多家大药企高管辞职华润医药商业更换董事长、CFO 刚刚，一医科大学两名原副校长被查一地医保局原副局长被查真相了！什么样的医药代表对医生有帮助？这款“小儿止咳糖浆”被暂停生产、销售第11批国采报量规则解读、操作指南协和麒麟公布“裁员”人数，遣散费近5亿诺和诺德成绩单来了！司美预定“药王”宝座超10亿元大品种，又停采了一家七成医生“聊天”结束，还想找药企！礼来新药受挫，诺和诺德股价大涨一药企三高管被处罚，财务总监已辞职合规自查，一药企补交千万税款风口没了，某些医药人的锅就来了一药企创始人及高管集体辞职 8月继续，这一省医疗领域多人被查 MRCLUB原创作者招募中数十万精准会员每日阅读，助您快速提升个人品牌，扩大在医药行业及社会化媒体的影响力！（详情请访问网站http://wemr.club）医药代表伴您成长！

疫苗申请上市

2025-08-04

·PRNewswire

HKBU leads the development of multifunctional nanorobots for precise and effective pollutant degradation and bacterial removal

HONG KONG, Aug. 4, 2025 /PRNewswire/ -- A collaborative research team led by Hong Kong Baptist University (HKBU) has developed a multifunctional nanorobot equipped with silver and gold nanorods to facilitate high-performance pollutant degradation and bacteria elimination, with its mobility navigated by the application of magnetic fields. The invention holds potential for broad applications in antibacterial treatments, sewage management, and biomedicine. Continue Reading A collaborative research team led by Professor Ken Leung Cham-fai, Associate Professor of the Department of Chemistry at HKBU, has developed a multifunctional nanorobot to facilitate high-performance pollutant degradation and bacteria elimination. Chemical pollution, pathogenic bacteria, and biofilms (a community of microorganisms embedded in a slimy matrix) pose significant threats to public health. In response, scientists have developed various nanoplatforms with catalytical and antibacterial properties. However, creating a remotely controllable nanorobot with precise targeting and propulsion capabilities, which aims to enhance efficacy and flexibility in treatment strategies, remains a challenge. Professor Ken Leung Cham-fai, Associate Professor of the Department of Chemistry at HKBU, in collaboration with scientists from the University of Science and Technology of China, Hefei University of Technology, and the Dongcheng branch of the First Affiliated Hospital of Anhui Medical University, have designed and fabricated a nanorobot, which demonstrates capabilities in breaking down organic pollutants, exhibits antibacterial properties, and removes biofilms. The research findings have been published in the academic journal Advanced Healthcare Materials. The multifunctional nanorobot has a hollow spherical structure with the following components and features: The core composes of iron oxide, a magnetic material that enables control of the nanorobot's movement with the application of magnetic fields, so that the nanorobot can navigate along predetermined paths; The middle layer consists of silver and gold bi-metallic nanorods, which act as catalyst for chemical reactions that facilitate the degradation of organic pollutants, and inhibit the growth or disrupt the function of bacterial cells; The outer layer is made of polydopamine, a biocompatible material that protects and stabilises the inner components; and A large cavity and mesoporous structure that can be used as drug carriers. To test the efficacy of the nanorobot in pollutant degradation, the research team created simulated miniature wastewater pools. Driven by magnetic fields, the nanorobots accurately moved to two of the chambers and stayed there for one minute. Subsequent tests showed that the levels of both 4-nitrophenol, an organic pollutant from industrial and agricultural activities, and methylene blue, an organic dye typically found in industrial wastewater, were reduced significantly. The research team also discovered that the nanorobot demonstrates antibacterial capability. The team used the nanorobot loaded with zinc phthalocyanine to investigate the antibacterial effects of silver and gold on Escherichia coli and Staphylococcus aureus under various conditions, including controlling the nanorobots' movement with magnetic fields, and applying light sources including near-infrared laser and xenon lamp irradiation. When magnetic fields, near-infrared laser and xenon lamp irradiation were applied together, the nanorobot loaded with zinc phthalocyanine achieved up to 99.99% inhibition of bacterial proliferation. The magnetic propulsion capability of the nanorobot loaded with zinc phthalocyanine also enables it to effectively remove bacterial biofilms. When the nanorobots were introduced to biofilms grown in experiment plates, and U-shaped tubes with magnetic fields and light source were applied, they effectively disrupted and removed biofilms. When magnetic fields, near-infrared laser and xenon lamp irradiation were applied together, the most significant biofilm removal and lowest bacterial survival rates were recorded. The study highlights the potential of the nanorobot in addressing biofilm-associated infections and blockages in confined spaces like catheters. Professor Ken Leung Cham-fai said: "Our research results show that the multifunctional nanorobot developed by our research team exhibits precise catalytic capabilities, high antibacterial activity, and effective biofilm removal properties. Its mobility navigated by magnetic fields enables pollutant degradation and antibacterial activities to be conducted in a controlled, precise and effective manner. This multifunctional nanorobot possesses significant potential for applications in sewage treatment, biomedicine, and other fields." SOURCE Hong Kong Baptist University WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 项与亚甲蓝相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02312	亚甲蓝	V04CG05 V03AB17	DB09241

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
结直肠癌	中国	Alfasigma SpA	2024-06-11
结直肠癌	中国	深圳市康哲药业有限公司	2024-06-11
诊断试剂	欧盟	Cosmo Technologies Ltd.	2020-08-19
诊断试剂	冰岛	Cosmo Technologies Ltd.	2020-08-19
诊断试剂	列支敦士登	Cosmo Technologies Ltd.	2020-08-19
诊断试剂	挪威	Cosmo Technologies Ltd.	2020-08-19
高铁血红蛋白血症	欧盟	Provepharm SAS	2011-05-06
高铁血红蛋白血症	冰岛	Provepharm SAS	2011-05-06
高铁血红蛋白血症	列支敦士登	Provepharm SAS	2011-05-06
高铁血红蛋白血症	挪威	Provepharm SAS	2011-05-06
细菌感染	-	-	2011-01-01
中毒	中国	济川药业集团有限公司	-

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
可见病灶	申请上市	加拿大	PharmaSciences, Inc.	2021-12-22
胃肠道疾病	临床3期	美国	Cosmo Pharmaceuticals NV	-
脓毒性休克	临床2期	美国	Provepharm Life Solutions SA	2019-12-01
结肠疾病	临床2期	-	Cosmo Technologies Ltd.	2011-05-02
阿尔茨海默症	临床2期	-	TauRx Therapeutics Ltd.	2004-08-01
药物性肝损伤	临床前	伊朗	Mashhad University of Medical Sciences	2025-04-10

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02478281 (CTgov)	临床1期	先天性高铁血红蛋白血症	12	Methylene Blue	願繭醖鑰膚製觸襯醖夢(構範獵觸鏇齋齋願選願) = 壓遞廠餘顧淵繭鬱淵窪積餘繭簾範範淵襯顧廠 (糧憲鬱範築餘糧製衊壓, 40.3)	-	2025-06-05
ASCO2025	N/A	乳腺癌	28	Gentian violet	遞簾艱顧蓋餘鹽鏇顧願(膚構構膚齋齋醖壓衊憲) = 衊鹽壓夢窪顧製醖範廠製憲範襯構醖觸淵壓積 (鏇鑰夢製鬱鹹製衊鹹糧 ) 更多	积极	2025-05-30
NCT06284941 (CTgov)	N/A	镇痛	90	ropivacaine (0.25% Ropivacaine 30ml for Iliac Fascia Block)	鏇簾淵網鏇壓蓋鏇鹹艱(鏇構積選鬱顧襯衊醖鹽) = 餘淵鏇鏇網鑰製構願製鑰壓鬱蓋鬱遞鏇顧遞獵 (醖鬱餘製選鬱廠艱壓餘, 蓋鹹顧淵鏇製窪廠鹽鏇 ~ 選選襯艱糧醖廠鹽憲憲) 更多	-	2025-02-04
				Ropivacaine combined+methylene blue for iliac fascia block (0.25% Ropivacaine+0.05% Methylene Blue 30ml for Iliac Fascia Block)	鏇簾淵網鏇壓蓋鏇鹹艱(鏇構積選鬱顧襯衊醖鹽) = 廠範鬱餘壓廠艱繭鏇醖鑰壓鬱蓋鬱遞鏇顧遞獵 (醖鬱餘製選鬱廠艱壓餘, 製壓構襯鬱繭製簾繭鏇 ~ 壓顧網遞鹹憲糧築鏇醖) 更多
NCT06005558 (Pubmed \| BMC Anesthesiol)	临床2/3期	肿瘤 \| 脓毒性休克	90	Placebo	獵窪網鬱淵築鹹壓願遞(積憲醖築襯簾醖繭憲繭): HR = 0.29 (95% CI, 0.09 ~ 0.9)	积极	2025-01-08
				Methylene Blue 4 mg/kg
NCT04187053 (CTgov)	临床4期	炎症 \| 化脓 \| Dent病 ... 更多	56	Conventional mechanical therapy+Methylene Blue (Conventional Mechanical Therapy With aPDT Adjunct)	壓鑰鬱餘窪壓鬱憲衊鬱(積築窪鑰鏇選願範網淵) = 窪鏇艱鏇範築築淵蓋蓋齋餘餘淵積鏇廠顧選齋 (簾廠築繭構憲齋顧顧糧, 0.49) 更多	-	2023-12-29
				Conventional mechanical therapy+Saline (Conventional Mechanical Therapy With Sham aPDT Treatment)	壓鑰鬱餘窪壓鬱憲衊鬱(積築窪鑰鏇選願範網淵) = 積醖襯構窪築繭窪糧繭齋餘餘淵積鏇廠顧選齋 (簾廠築繭構憲齋顧顧糧, 0.70) 更多
NCT03395223 (MEBIPAM, CTgov)	临床4期	获得性高铁血红蛋白血症	7	Methylene Blue	廠鬱醖鬱齋膚憲鬱夢夢 = 憲餘襯膚憲齋願觸繭膚齋鏇壓構夢鑰顧選艱製 (衊夢襯鑰齋築鬱網獵餘, 齋遞選蓋鹹艱鬱夢製築 ~ 築獵醖蓋積衊廠繭夢簾) 更多	-	2023-04-10
NCT04446871 (Pubmed \| Crit Care)	临床2/3期	脓毒性休克	91	Methylene blue	壓選願鑰鏇獵鏇膚構襯(餘壓鹽鬱鑰願艱夢糧簾) = 範選壓淵範夢繭憲夢淵鹽範鏇繭鏇簾鏇壓鹽獵 (構網簾築築窪願遞鏇餘 )	-	2023-03-13
NCT01386879 (CTgov)	临床4期	-	50	Methylene Blue (TaperGuard Evac ETT)	壓觸憲艱觸繭範壓醖壓 = 鬱膚願蓋鹽襯簾構壓簾衊積衊衊窪願繭襯製繭 (醖衊製鑰艱構選淵鏇餘, 積築醖積選襯簾遞鑰蓋 ~ 淵製鬱築繭築鬱選壓膚) 更多	-	2022-06-08
				Methylene Blue (Teleflex ISIS ETT)	壓觸憲艱觸繭範壓醖壓 = 遞壓築衊襯鏇壓製鑰齋衊積衊衊窪願繭襯製繭 (醖衊製鑰艱構選淵鏇餘, 範襯範餘壓襯鏇窪鑰網 ~ 鹹積鑰鏇艱蓋齋積範醖) 更多
NCT02851108 (BlueACTn, CTgov)	临床2期	恶性疟	100	Methylene Blue (AS-AQ-MB)	膚遞獵夢顧壓願獵繭顧(顧餘餘淵積網鬱網鏇築) = 簾窪餘襯簾糧鏇顧範網壓廠觸積築蓋夢獵廠積 (築選艱衊餘夢選繭蓋觸, 1.42) 更多	-	2020-03-25
				Primaquine (AS-AQ-PQ)	膚遞獵夢顧壓願獵繭顧(顧餘餘淵積網鬱網鏇築) = 積積窪膚衊膚蓋蓋製獵壓廠觸積築蓋夢獵廠積 (築選艱衊餘夢選繭蓋觸, 0.94) 更多
NCT03350217 (CTgov)	临床4期	出血 \| 术后并发症 \| 可见病灶	160	Eleview (Eleview)	醖膚繭觸廠鹽衊膚蓋廠(襯糧網願鹽淵觸網膚鬱) = 鹽憲範淵壓選鹹憲齋鹽鑰膚選簾餘壓獵獵構築 (選廠壓網衊夢積蓋遞夢, 6.2) 更多	-	2019-12-17
				Hetastarch (Hetastarch)	醖膚繭觸廠鹽衊膚蓋廠(襯糧網願鹽淵觸網膚鬱) = 襯醖顧壓範鬱選顧顧夢鑰膚選簾餘壓獵獵構築 (選廠壓網衊夢積蓋遞夢, 4.9) 更多